News | Biogen

September 1, 2021

Biogen to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Cambridge, MA.— Biogen Inc. (Nasdaq: BIIB) announced today that it will participate in a live Q&A at the Morgan Stanley 19th Annual Global Healthcare Conference. The webcast will be live on Thursday, September 9, at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section

August 2, 2021

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

July 29, 2021

Biogen to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

Biogen Idec to Report Fourth Quarter and Full Year 2007 Financial Results on February 6, 2008

FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease

Biogen Idec Announces Appointment of Nancy L. Leaming to Board of Directors

Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech

Biogen Idec Provides Business Update at Investor Meeting

Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis

Biogen Idec to Present at the 26th Annual JPMorgan Healthcare Conference